Get started
Author

Tomoyoshi Hatayama

Observed name: Hatayama, Tomoyoshi
ORCID: 0000-0002-4384-5148
Observed ORCID: 0000-0002-4384-5148
OpenAlex ID: A5064865821
Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study
2022 · Hirotsugu Uemura, Gaku Arai, et al. · International Journal of Urology · 26
PDF
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE ‐1 (phase 2) Japanese cohort
2022 · Masaki Ri, Kenshi Suzuki, et al. · Cancer Science · 23
PDF
Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study
2020 · Hirotsugu Uemura, Gaku Arai, et al. · International Journal of Urology · 20
PDF
Bayesian central statistical monitoring using finite mixture models in multicenter clinical trials
2020 · Tomoyoshi Hatayama, Seiichi Yasui · Contemporary Clinical Trials Communications · 9
PDF
Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
2022 · Takayuki Ikezoe, Kensuke Usuki, et al. · Cancer Science · 5
PDF
Bayesian response adaptive randomization using longitudinal outcomes
2015 · Tomoyoshi Hatayama, Satoshi Morita, et al. · Pharmaceutical Statistics · 5
Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study
2023 · Masako Toyosaki, Noriko Doki, et al. · BLOOD CELL THERAPY / The official journal of APBMT · 3
PDF
CUSUMIN : A cumulative sum interval design for cancer phase I dose finding studies
2022 · Tomoyoshi Hatayama, Seiichi Yasui · Pharmaceutical Statistics · 1
CUSUMIN Combination: A Cumulative Sum Interval Design for Phase I Cancer Drug‐Combination Trials
2025 · Tomoyoshi Hatayama, Seiichi Yasui · Pharmaceutical Statistics
PDF
A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia
2024 · Koji Izutsu, Hisashi Kato, et al. · International Journal of Hematology
PDF
Perspectives on Central Statistical Monitoring in Risk Based Approach of Clinical Trials
2021 · Hatayama, Tomoyoshi, Yasui, Seiichi · HAL
Works count: 11
Citation count: 92
H-index: 5
I10-index: 3
Year
Topic
Type